Physician profile

Frederick Charles David

Radiation Oncology · Santa Rosa, CA

NPI 1982793808

$7,069.26

in general payments reported to CMS, 2019-2025

50 companies · $989 in 2025

The $989 reported for 2025 was more than what 83% of Radiation Oncology providers received nationally (typical 2025 total: $172).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,116.09
Education$79.79

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $679.95 2019-2025 Enhertu, Imfinzi, Calquence
Daiichi Sankyo INC. $538.70 2019-2025 Enhertu, Datroway
Merck Sharp & Dohme LLC $440.02 2019-2025 Keytruda, Lynparza, Welireg
Regeneron Healthcare Solutions, INC. $405.12 2021-2025 Libtayo
Lilly USA, LLC $389.79 2019-2025 Jaypirca, Verzenio
Janssen Biotech, INC. $378.87 2019-2025 Erleada, Akeega, Balversa
Genzyme Corporation $376.23 2019-2022
Amgen INC. $355.00 2019-2022
E.R. Squibb & Sons, L.L.C. $308.36 2019-2024 Opdivo
Glaxosmithkline, LLC. $271.52 2020-2024 Ojjaara
Progenics Pharmaceuticals, INC. $266.40 2022-2023 Pylarify
Novartis Pharmaceuticals Corporation $237.80 2019-2025
Eisai INC. $202.70 2019-2022
Genentech USA, INC. $188.06 2021-2025 Tecentriq Hybreza, Itovebi
Bayer Healthcare Pharmaceuticals INC. $180.89 2019-2025
Show all 50 companies
CompanyGeneral paymentsYearsTop products
Pfizer INC. $167.57 2019-2024
Takeda Pharmaceuticals U.S.A., INC. $164.99 2019-2025 Ninlaro, Iclusig
Alexion Pharmaceuticals, INC. $159.85 2019-2023 Ultomiris
Celgene Corporation $152.16 2019-2022
Seagen INC. $121.81 2019-2023 Padcev
Pharmacyclics LLC, An Abbvie Company $120.00 2020-2022
Regeneron Pharmaceuticals, INC. $79.65 2025 Lynozyfic
Exelixis INC. $67.64 2019-2020
Rigel Pharmaceuticals, INC. $67.26 2019-2025 Gavreto, Tavalisse, Rezlidhia
Incyte Corporation $56.10 2020-2022
Myovant Sciences INC. $49.34 2021-2022
Gilead Sciences, INC. $46.70 2025 Trodelvy
Taiho Oncology, INC. $45.46 2022
Abbvie INC. $43.67 2021-2025
Astellas Pharma US INC $40.49 2021-2022
Agios Pharmaceuticals, INC. $37.97 2020
Boehringer Ingelheim Pharmaceuticals, INC. $37.97 2019-2025
Kyowa Kirin, INC. $35.15 2021-2022
Emd Serono, INC. $34.41 2021-2022
Ipsen Biopharmaceuticals, INC $30.85 2021
Adc Therapeutics America, INC. $29.69 2025
Palette Life Sciences, INC. $23.79 2023
Clovis Oncology, INC. $23.61 2020
Servier Pharmaceuticals LLC $23.48 2022
Foundation Medicine, INC. $22.81 2020
Sobi, INC $21.67 2022
Beigene USA, INC. $20.23 2021
Tersera Therapeutics LLC $18.37 2022
Karyopharm Therapeutics INC. $18.25 2021
Jazz Pharmaceuticals INC. $17.64 2021
Zap Surgical Systems, INC. $17.51 2021
Boston Scientific Corporation $17.21 2022
Epizyme, INC. $16.88 2021
Organon LLC $14.71 2021
Secura Bio, INC. $4.96 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Frederick Charles David

$7,069.26

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals LP
Context
The $989 reported for 2025 was more than what 83% of Radiation Oncology providers received nationally (typical 2025 total: $172).

https://glasscript.com/doctor/316752/frederick-charles-david

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.